| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,380,000 |
| Market
Cap: |
35.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1 - $1.25 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Evofem Biosciences is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health, including woman-controlled contraception and protection from certain sexually transmitted infections. Co.'s commercial product, Phexxi, is the U.S. Food and Drug Administration (FDA)-approved, hormone-free, woman-controlled, prescription contraceptive gel for women. Co. is evaluating Phexxi for two potential new indications: the prevention of chlamydia and the prevention of gonorrhea in women. The FDA has designated Phexxi, using the investigational name EVO100, as a Qualified Infectious Disease Product.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
114 |
114 |
114 |
| Total Sell Value |
$0 |
$10 |
$10 |
$10 |
| Total People Sold |
0 |
2 |
2 |
2 |
| Total Sell Transactions |
0 |
2 |
2 |
2 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barrans Russell |
Chief Commercial Officer |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$4,684 |
D/D |
150,899 |
347,197 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2020-02-05 |
4 |
A |
$0.00 |
$19,214 |
D/D |
153,688 |
197,226 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2020-01-16 |
4 |
AS |
$6.50 |
$10,257 |
D/D |
(1,578) |
196,298 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2020-01-02 |
4 |
AS |
$6.05 |
$40,565 |
D/D |
(6,705) |
365,584 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2020-01-02 |
4 |
AS |
$6.05 |
$20,280 |
D/D |
(3,352) |
178,899 |
|
- |
|
| Lynch Thomas G |
Director |
– • – |
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
287,500 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2019-12-02 |
4 |
AS |
$7.30 |
$146,000 |
D/D |
(20,000) |
372,289 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2019-12-02 |
4 |
AS |
$7.35 |
$7,350 |
D/D |
(1,000) |
43,538 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2019-12-02 |
4 |
AS |
$7.16 |
$71,600 |
D/D |
(10,000) |
182,251 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2019-11-25 |
4 |
D |
$6.22 |
$62,834 |
D/D |
(10,102) |
192,251 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2019-11-25 |
4 |
D |
$6.22 |
$32,263 |
D/D |
(5,187) |
44,538 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2019-11-25 |
4 |
D |
$6.22 |
$48,186 |
D/D |
(7,747) |
63,331 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2019-11-25 |
4 |
D |
$6.22 |
$57,703 |
D/D |
(9,277) |
197,876 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2019-11-25 |
4 |
D |
$6.22 |
$139,247 |
D/D |
(22,387) |
392,289 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2019-11-21 |
4 |
AS |
$6.01 |
$60,100 |
D/D |
(10,000) |
414,676 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2019-11-21 |
4 |
AS |
$6.00 |
$29,400 |
D/D |
(4,900) |
202,353 |
|
- |
|
| Pelletier Saundra L |
Chief Executive Officer |
• • – |
2019-11-20 |
4 |
D |
$5.74 |
$130,051 |
D/D |
(22,657) |
424,676 |
|
- |
|
| Barrans Russell |
Chief Commercial Officer |
• – – |
2019-11-20 |
4 |
D |
$5.74 |
$51,913 |
D/D |
(9,044) |
207,153 |
|
- |
|
| Culwell Kelly |
Chief Medical Officer |
• – – |
2019-11-20 |
4 |
D |
$5.74 |
$29,773 |
D/D |
(5,187) |
49,725 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2019-11-20 |
4 |
D |
$5.74 |
$44,468 |
D/D |
(7,747) |
71,078 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2019-11-20 |
4 |
AS |
$6.00 |
$600 |
D/D |
(100) |
207,253 |
|
- |
|
| File Justin J. |
Chief Financial Officer |
• – – |
2019-11-20 |
4 |
D |
$5.74 |
$57,985 |
D/D |
(10,102) |
207,353 |
|
- |
|
| Fitzpatrick Alexander A |
General Counsel and Secretary |
• – – |
2019-10-16 |
4 |
D |
$5.01 |
$92,319 |
D/D |
(18,427) |
78,825 |
|
- |
|
| Link Fund Solutions Ltd |
10% Owner |
– – • |
2019-10-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,087,206 |
|
- |
|
| Lynch Thomas G |
Director |
– • – |
2019-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
250,000 |
|
- |
|
194 Records found
|
|
Page 4 of 8 |
|
|
